Immune checkpoint inhibitors and myocardial infarction.

IF 2.3 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Thrombosis and Thrombolysis Pub Date : 2025-03-10 DOI:10.1007/s11239-025-03081-7
Vencel Juhasz, Giselle Alexandra Suero-Abreu, Tomas G Neilan
{"title":"Immune checkpoint inhibitors and myocardial infarction.","authors":"Vencel Juhasz, Giselle Alexandra Suero-Abreu, Tomas G Neilan","doi":"10.1007/s11239-025-03081-7","DOIUrl":null,"url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy since their first approval in 2011. By unleashing the adaptive immune system, non-cardiac and cardiac immune-related adverse events (irAEs) are common and often pose a challenge to multidisciplinary teams treating cancer patients. A significant body of literature reports accelerated atherosclerosis - a key precursor of acute vascular events (AVEs) - with currently approved ICIs (CTLA-4, PD-1, LAG-3, and PD-L1 inhibitors), and some preclinical research also suggests increased thrombogenicity. A large meta-analysis has reported an increased incidence of AVEs, including myocardial infarction (MI) and stroke with ICIs. In addition, dyslipidemia secondary to ICI use may lead to an increase in cardiovascular (CV) events in long-term cancer survivors. Currently, there are no specific guidelines for the treatment of MI or CV risk in cancer patients with ICIs. Overall survival (≥ 6 months), thrombogenic, and bleeding risk are key determinants in choosing the appropriate acute approach and antithrombotic therapy, while other principles of MI management do not differ between cancer and non-cancer patients. Future avenues of research include lipid-lowering therapies, including PCSK9 inhibitors and statins, which may offer dual beneficial effects by improving anti-cancer efficacy and reducing CV risk. In addition, newer immune checkpoint targets may provide atheroprotection while being effective against certain cancers (e.g., CD47). Given the tremendous potential of ICIs, intensive research is warranted to reduce CV risk and the incidence of AVE, including MI, in active cancer patients and survivors.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Thrombolysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11239-025-03081-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy since their first approval in 2011. By unleashing the adaptive immune system, non-cardiac and cardiac immune-related adverse events (irAEs) are common and often pose a challenge to multidisciplinary teams treating cancer patients. A significant body of literature reports accelerated atherosclerosis - a key precursor of acute vascular events (AVEs) - with currently approved ICIs (CTLA-4, PD-1, LAG-3, and PD-L1 inhibitors), and some preclinical research also suggests increased thrombogenicity. A large meta-analysis has reported an increased incidence of AVEs, including myocardial infarction (MI) and stroke with ICIs. In addition, dyslipidemia secondary to ICI use may lead to an increase in cardiovascular (CV) events in long-term cancer survivors. Currently, there are no specific guidelines for the treatment of MI or CV risk in cancer patients with ICIs. Overall survival (≥ 6 months), thrombogenic, and bleeding risk are key determinants in choosing the appropriate acute approach and antithrombotic therapy, while other principles of MI management do not differ between cancer and non-cancer patients. Future avenues of research include lipid-lowering therapies, including PCSK9 inhibitors and statins, which may offer dual beneficial effects by improving anti-cancer efficacy and reducing CV risk. In addition, newer immune checkpoint targets may provide atheroprotection while being effective against certain cancers (e.g., CD47). Given the tremendous potential of ICIs, intensive research is warranted to reduce CV risk and the incidence of AVE, including MI, in active cancer patients and survivors.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.20
自引率
0.00%
发文量
112
审稿时长
4-8 weeks
期刊介绍: The Journal of Thrombosis and Thrombolysis is a long-awaited resource for contemporary cardiologists, hematologists, vascular medicine specialists and clinician-scientists actively involved in treatment decisions and clinical investigation of thrombotic disorders involving the cardiovascular and cerebrovascular systems. The principal focus of the Journal centers on the pathobiology of thrombosis and vascular disorders and the use of anticoagulants, platelet antagonists, cell-based therapies and interventions in scientific investigation, clinical-translational research and patient care. The Journal will publish original work which emphasizes the interface between fundamental scientific principles and clinical investigation, stimulating an interdisciplinary and scholarly dialogue in thrombosis and vascular science. Published works will also define platforms for translational research, drug development, clinical trials and patient-directed applications. The Journal of Thrombosis and Thrombolysis'' integrated format will expand the reader''s knowledge base and provide important insights for both the investigation and direct clinical application of the most rapidly growing fields in medicine-thrombosis and vascular science.
期刊最新文献
Recanalization is more important than procedure time on outcome of thrombectomy in acute vertebrobasilar artery occlusion. Intravenous thrombolysis with tenecteplase versus alteplase in acute ischemic stroke tandem occlusions: a systematic review and meta-analysis of current available literature. Immune checkpoint inhibitors and myocardial infarction. Incidence of arterial and venous thromboembolism in cancer patients- insights from more than 5,000,000 patients. Predictors of venous thromboembolic events in hospitalized patients with COVID-19.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1